Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone PK Study of M107 ODT and Duvie in Healthy Adults
NCT07056517Phase 1Completed
- Sponsor
- Aclipse Two
- Start
- Jul 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (3 cohorts), sponsored by Aclipse Two. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and clinically significant abnormalities at 15 days, Maximum observed plasma concentration at 48 hours and 11 more. Started Jul 2025; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07056517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056517.